CAR T-cell therapy produces deep, sustained remissions in patients with relapsed myeloma
26 Feb, 2021 | 08:31h | UTCOriginal study: Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma – New England Journal of Medicine
Original study: Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma – New England Journal of Medicine